Iradimed Corp (IRMD)
NASDAQ:IRMD
IRMD Stock Chart & Stats
$76.42
$0.29(0.51%)
At close: 4:00 PM EST
$76.42
$0.29(0.51%)
Day’s Range― - ―
52-Week Range$47.48 - $107.90
Previous CloseN/A
Volume15.52K
Average Volume (3M)68.84K
Market Cap
$1.30B
Enterprise Value$1.25B
Total Cash (Recent Filing)$51.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)55.1
Beta0.76
Next Earnings
Apr 24, 2026EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend Yield1.22%
Share Statistics
EPS (TTM)0.54
Shares Outstanding12,782,566
10 Day Avg. Volume79,086
30 Day Avg. Volume68,837
Financial Highlights & Ratios
PEG Ratio3.35
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue14.91
Enterprise Value/Gross Profit19.43
Enterprise Value/Ebitda43.20
Forecast
1Y Price Target
$120.00Price Target Upside57.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.12
Revenue Forecast (FY)$91.10M
Bulls Say, Bears Say
Bulls Say
Sustained High ProfitabilityConsistently high gross and operating margins and expanding net margins indicate durable pricing power and tight cost control in a niche MRI-compatible devices market. This margin profile supports sustained cash generation and reinvestment capacity, making core profitability resilient over 2–6 months.
Exceptionally Conservative Balance SheetNear-zero debt and growing equity/assets provide strong financial flexibility to fund the 3870 ramp, absorb temporary margin pressure, pay dividends, or invest in international regulatory efforts without forcing dilutive financing, lowering long-term solvency risk.
Large, Structural Product Opportunity (3870 Launch)The 3870 represents a structural growth driver: ASP uplift and a defined replacement TAM (~6,400 eligible U.S. channels) plus recurring disposables and service create durable revenue and margin expansion potential if clinical adoption and manufacturing scale proceed as planned.
Bears Say
High U.S. Revenue ConcentrationHeavy reliance on the U.S. market exposes results to domestic hospital purchasing cycles, reimbursement changes, or demand shifts. Delayed international regulatory approvals limit geographic diversification, leaving revenue and growth sensitive to U.S. execution over the next several quarters.
Operational Transition And Margin RiskThe 3860→3870 transition creates execution risk: elevated inventory, constrained initial volumes and subscale production can depress margins and strain working capital. Successful scaling is required to realize ASP benefits; any ramp delays would have multi-quarter impact on profitability.
Cash-flow Volatility And Slowing GrowthWhile FCF is positive, historical volatility and instances where operating cash lagged earnings reduce predictability of internal funding for growth. Coupled with a recent slowdown in revenue growth, this elevates execution risk for ambitious 2026 targets if cash conversion weakens again.
Iradimed News
IRMD FAQ
What was Iradimed Corp’s price range in the past 12 months?
Iradimed Corp lowest stock price was $47.48 and its highest was $107.90 in the past 12 months.
What is Iradimed Corp’s market cap?
Iradimed Corp’s market cap is $1.30B.
When is Iradimed Corp’s upcoming earnings report date?
Iradimed Corp’s upcoming earnings report date is Apr 24, 2026 which is in 28 days.
How were Iradimed Corp’s earnings last quarter?
Iradimed Corp released its earnings results on Feb 10, 2026. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.06.
Is Iradimed Corp overvalued?
According to Wall Street analysts Iradimed Corp’s price is currently Undervalued.
Does Iradimed Corp pay dividends?
Iradimed Corp pays a Monthly dividend of $0.5 which represents an annual dividend yield of 1.22%. See more information on Iradimed Corp dividends here
What is Iradimed Corp’s EPS estimate?
Iradimed Corp’s EPS estimate is 0.45.
How many shares outstanding does Iradimed Corp have?
Iradimed Corp has 12,782,566 shares outstanding.
What happened to Iradimed Corp’s price movement after its last earnings report?
Iradimed Corp reported an EPS of $0.54 in its last earnings report, beating expectations of $0.48. Following the earnings report the stock price went up 9.565%.
Which hedge fund is a major shareholder of Iradimed Corp?
Currently, no hedge funds are holding shares in IRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iradimed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$120.00 (57.03% Upside)
$120.00 (57.03% Upside)
Blogger Sentiment
Bullish
IRMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 11.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $100.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.84%
12-Months-Change
Fundamentals
Return on Equity
23.83%
Trailing 12-Months
Asset Growth
10.63%
Trailing 12-Months
Company Description
Iradimed Corp
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
IRMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was largely positive: management reported broad-based, double-digit revenue growth, improved EPS, strong gross margins, healthy cash balances, and encouraging early demand and ASP uplift potential from the new 3870 pump. Key risks center on the operational transition from the legacy 3860 to the 3870 (inventory management and subscale margin pressure early in the ramp), geographic concentration in the U.S., and delayed international regulatory clearances. Provided execution on manufacturing ramp, sales bookings, and hospital adoption proceeds as planned, the company is positioned for meaningful revenue acceleration in 2026; however, near-term operational and timing risks merit monitoring.View all IRMD earnings summariesIRMD Stock 12 Month Forecast
Average Price Target
$120.00
▲(57.03% Upside)
Technical Analysis
Ownership Overview
35.47% Insiders
12.84% Mutual Funds
17.23% Other Institutional Investors
25.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---